Skip to main content
. Author manuscript; available in PMC: 2017 Jan 12.
Published in final edited form as: Vaccine. 2015 Dec 2;34(3):313–319. doi: 10.1016/j.vaccine.2015.11.056

Table 3.

Vaccine Efficacy

CMV gB/MF59 Placebo
n CMV infection (%) N n CMV infection (%) N Vaccine Efficacy (%) [1] 95% CI for Vaccine Efficacy [2] P-value [3]
CMV Infection after 3 Doses
 Per Protocol after 3 Doses 8 (6.5%) 124 14(11.2%) 125 42.9 −36.2, 76.0 0.200
 Intention to Treat after 3 Doses 13 (7.7%) 168 18 (9.9%) 181 23.2 −56.7, 62.4 0.466
CMV Infection after 2 Doses
 Per Protocol after 2 Doses 13 (7.9%) 164 24 (14.0%) 172 44.5 −8.9, 71.8 0.082
 Intention to Treat after 2 Doses 20 (10.8%) 186 25 (12.6%) 199 15.0 −53.1, 52.8 0.589
CMV Infection after 1 Dose
 Per Protocol after 1 Dose 18 (9.5%) 189 26(13.5%) 192 30.7 −26.4, 62.0 0.229
 Intention to Treat after 1 Dose 21 (10.8%) 195 27 (13.2%) 205 18.5 −44.1, 53.9 0.480

Note: N = Number of subjects in specific treatment group. n = Number of subjects with CMV infection.

[1]

Vaccine efficacy is obtained from Cox regression.

[2]

95% CI = 95% confidence interval obtained from Cox regression.

[3]

P-value = result of comparison of Kaplan-Meier survival curves between groups by Log-rank test.